Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Avery

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Brain Stimulation|June 18, 2013
The painfulness of active, but not sham, transcranial magnetic stimulation decreases rapidly over time: results from the double-blind phase of the OPT-TMS TrialJeffrey J Borckardt, Ziad H Nahas, John Teal, et al.
Depression and Anxiety|September 8, 2011
Improving the antidepressant efficacy of transcranial magnetic stimulation: maximizing the number of stimulations and treatment location in treatment-resistant depressionWilliam M McDonald, Valerie Durkalski, Edward R Ball, et al.
Archives of General Psychiatry|May 5, 2010
Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trialMark S George, Sarah H Lisanby, David Avery, et al.
Transfusion|September 29, 2020
Provision of COVID-19 Convalescent Plasma in a Resource-Constrained StateTina S Ipe, Tuan Le, Brian Quinn, et al.
Brain Stimulation|April 3, 2012
Prefrontal rTMS for treating depression: location and intensity results from the OPT-TMS multi-site clinical trialKevin A Johnson, Mirza Baig, Dave Ramsey, et al.
Biological Psychiatry|November 17, 2009
Reply regarding "efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial"John P O'Reardon, H Brent Solvason, Philip G Janicak, et al.
Biological Psychiatry|June 19, 2007
Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trialJohn P O'Reardon, H Brent Solvason, Philip G Janicak, et al.
ACS Nano|August 9, 2013
A multi-stakeholder perspective on the use of alternative test strategies for nanomaterial safety assessmentAndre E Nel, Elina Nasser, Hilary Godwin, et al.
ACS Nano|March 21, 2015
Nanomaterial categorization for assessing risk potential to facilitate regulatory decision-makingHilary Godwin, Catherine Nameth, David Avery, et al.
Environmental Science & Technology|May 14, 2016
Considerations of Environmentally Relevant Test Conditions for Improved Evaluation of Ecological Hazards of Engineered NanomaterialsPatricia A Holden, Jorge L Gardea-Torresdey, Fred Klaessig, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Brain Stimulation|June 18, 2013
The painfulness of active, but not sham, transcranial magnetic stimulation decreases rapidly over time: results from the double-blind phase of the OPT-TMS TrialJeffrey J Borckardt, Ziad H Nahas, John Teal, et al.
Depression and Anxiety|September 8, 2011
Improving the antidepressant efficacy of transcranial magnetic stimulation: maximizing the number of stimulations and treatment location in treatment-resistant depressionWilliam M McDonald, Valerie Durkalski, Edward R Ball, et al.
Archives of General Psychiatry|May 5, 2010
Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trialMark S George, Sarah H Lisanby, David Avery, et al.
Transfusion|September 29, 2020
Provision of COVID-19 Convalescent Plasma in a Resource-Constrained StateTina S Ipe, Tuan Le, Brian Quinn, et al.
Brain Stimulation|April 3, 2012
Prefrontal rTMS for treating depression: location and intensity results from the OPT-TMS multi-site clinical trialKevin A Johnson, Mirza Baig, Dave Ramsey, et al.
Biological Psychiatry|November 17, 2009
Reply regarding "efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial"John P O'Reardon, H Brent Solvason, Philip G Janicak, et al.
Biological Psychiatry|June 19, 2007
Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trialJohn P O'Reardon, H Brent Solvason, Philip G Janicak, et al.
ACS Nano|August 9, 2013
A multi-stakeholder perspective on the use of alternative test strategies for nanomaterial safety assessmentAndre E Nel, Elina Nasser, Hilary Godwin, et al.
ACS Nano|March 21, 2015
Nanomaterial categorization for assessing risk potential to facilitate regulatory decision-makingHilary Godwin, Catherine Nameth, David Avery, et al.
Environmental Science & Technology|May 14, 2016
Considerations of Environmentally Relevant Test Conditions for Improved Evaluation of Ecological Hazards of Engineered NanomaterialsPatricia A Holden, Jorge L Gardea-Torresdey, Fred Klaessig, et al.
Pageof 4